The remarkable synergistic effect we observed may be partly explained by the route of administration—intraperitoneal injection of quinacrine and TRAIL, instead of oral delivery and systemic injection, respectively, which we hypothesize may lead to longer exposure of cancer cells to therapeutic agents in higher concentrations within the peritoneum. The gene discussed is TNFSF10; the disease is cancer.